Detalles de la búsqueda
1.
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.
Oncologist
; 29(4): 303-310, 2024 Apr 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37995313
2.
Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach.
Cancer Immunol Immunother
; 72(7): 2217-2231, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-36869232
3.
Circulating CD137+ T Cell Levels Are Correlated with Response to Pembrolizumab Treatment in Advanced Head and Neck Cancer Patients.
Int J Mol Sci
; 24(8)2023 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37108276
4.
The role of opioids in cancer response to immunotherapy.
J Transl Med
; 19(1): 119, 2021 03 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-33757546
5.
5-Fluorouracil degradation rate as a predictive biomarker of toxicity in breast cancer patients treated with capecitabine.
J Oncol Pharm Pract
; 26(8): 1836-1842, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32131682
6.
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.
J Cell Physiol
; 234(6): 7708-7717, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30536609
7.
Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study.
Front Oncol
; 13: 1280416, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38023235
8.
The Impact of Drug-Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma.
Cancers (Basel)
; 15(18)2023 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37760556
9.
Network approach in liquidomics landscape.
J Exp Clin Cancer Res
; 42(1): 193, 2023 Aug 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37542343
10.
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study.
Front Oncol
; 13: 1177681, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37441419
11.
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study.
J Natl Cancer Inst
; 115(7): 796-804, 2023 07 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37042716
12.
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study.
Front Oncol
; 13: 1152123, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37260975
13.
The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature.
Front Oncol
; 12: 797157, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35223478
14.
Immune effects of CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: Relief from immunosuppression is associated with clinical response.
EBioMedicine
; 79: 104010, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35477069
15.
The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy.
Front Immunol
; 13: 974087, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36405727
16.
Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer.
Cancers (Basel)
; 13(5)2021 Mar 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33802438
17.
The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study.
J Pers Med
; 11(7)2021 Jul 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34357118
18.
Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis.
Front Immunol
; 12: 705096, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34434192
19.
Second medical opinion in oncological setting.
Crit Rev Oncol Hematol
; 160: 103282, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33675905
20.
CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives.
Cancers (Basel)
; 13(2)2021 Jan 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-33477469